Saneca Pharmaceuticals, a.s. has acquired Suir Pharma Ireland
Saneca Pharmaceuticals, a.s. (Saneca) has acquired Suir Pharma Ireland from mutares AG, an industrial holding company. Financial details have not been disclosed.
Saneca is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns a portfolio of cosmetic and generic products.
Suir Pharma Ireland is an independent contract manufacturing company working with many established pharmaceutical companies worldwide. Formerly a Stada AG manufacturing site, Suir Pharma Ireland is well known as an established manufacturer of generic medicines for more than 40 years with the highest quality standards. The company supplies various markets in Europe and the USA.
mutares AG is an industrial holding company that focuses on the acquisition of companies currently finding themselves in a special situation, such as owner or management succession, strategic repositioning and re-funding.
Oaklins' team in Slovakia advised the buyer in this transaction.
Talk to the deal team
Related deals
Bluegem Capital Partners and AREV Partners have acquired 100% of Groupe Pinard
Bluegem Capital Partners and AREV Partners have successfully completed the acquisition of the prestigious Groupe Pinard from IK Partners.
Learn moreLumiforte partners with Kartesia to propel global growth and innovation
Lumiforte, a global leader in innovative smart coatings for greenhouse horticulture, sports line-marking and other functional coatings for agriculture and industry, is excited to announce an investment from Kartesia, a European specialist in capital solutions for small and medium-sized companies. Horticoop, a longstanding shareholder of Lumiforte and a key player in the horticultural industry through its investment cooperative, continues to remain a shareholder.
Learn morePanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production
PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.
Learn more